Skip to main content
Equibles
TELO logo

TELO · Telomir Pharmaceuticals, Inc.

Track TELO — free

Use TELO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TELO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.01 -0.04 (-3.37%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issuance date of this Report.”
View the 10-Q filed Aug 13, 2026
Market Cap
$71.53M
Shares
68.77M
Volume · Oct 20 76.26K Avg daily vol (3M) 95.41K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.04 Open$1.05 Day$1.03–1.10 52W close$0.92–1.66 Avg vol 30d118K Short int826K · 1.2% float · 8.3d Short vol67% DataFeb 2024–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$5.88M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$754,323
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+102.7%
Year over year · more shares
Price change (1Y)
-33.8%
Trailing year
Short interest
1.2%
Latest settlement · 8.3 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −10%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 16%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −28%
trailing
YTD return −22%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
4 of 33 funds reported for Sep 30 · net -24.1K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.20% of float · ▲ +6.3% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 2-yr range
Squeeze score 56
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −45%
past year
ATR 7.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
4 of 33 funds reported for Sep 30 · net -24.1K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.20% of float · ▲ +6.3% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 16% Range high $2
vs 200-day avg -16% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TELO
Telomir Pharmaceuticals, Inc.
this stock
$71.53M -21.8% — — 1.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
32
% held
4.3%
Reported
4 of 33
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Rising
Shares short
825.7K
Days to cover
8.3d
Change
+48.6K sh
View
Short Volume
Short vol %
67%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
910
Value
$1.1K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
38.1%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-10.4M
EPS diluted
$-0.33
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 6, 2026
This year
21
View
Exempt Offerings
Offering
$1.0M
Filed
Apr 3, 2023
View

Performance

5D 20D 120D MTD YTD
TELO -5.5% -16.1% -28.3% -13.3% -21.8%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -4.0% -15.2% -36.0% -13.8% -34.2%
Key facts CIK 1971532 CUSIP 87975F104 13F (30d) 3 filings 3 filers Visit website